An extension of AC-055-310, a multi-center, open-label, single-arm, Phase 3b study of macitentan in patients with pulmonary arterial hypertension to psychometrically validate the French, Italian and Spanish versions of the PAH-SYMPACT
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 28 Jul 2017
At a glance
- Drugs Macitentan (Primary)
- Indications Pulmonary arterial hypertension
- Focus Adverse reactions
- Acronyms ORCHESTRA Ext.
- Sponsors Actelion Pharmaceuticals
- 28 Jul 2017 The trial has been completed in Spain.
- 12 Apr 2017 Planned End Date changed from 1 Mar 2017 to 31 Mar 2018.
- 12 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 31 Mar 2018.